Eisai plans development, research facility in North Carolina for oncology treatments

By Jennifer Chiou

New York, Feb. 27 - Eisai Inc. announced it is preparing for a new pharmaceutical production and formulation research and development facility for parenteral or intravenous oncology treatments in Research Triangle Park, N.C.

"Oncology is one of Eisai's long-standing therapeutic areas of focus, supporting our human health care mission to increase benefits to patients and their families and satisfy unmet medical needs," president and chief operating officer Lonnel Coats said in a news release.

"Our plans for the new facility in RTP [Research Triangle Park] demonstrate Eisai's global commitment to oncology and patients around the world."

Groundbreaking on the $90 million, 65,000 square foot facility is expected in the fall, with operations estimated to begin in 2009.

The new facilities will lead to 59 new jobs over the next three years and a total of 84 new jobs over the next five years, the company said in the release.

Based in Teaneck, N.J., Eisai is a pharmaceutical subsidiary of Eisai Co., Ltd., a research-based human health care company focused on neurology, gastrointestinal disorders and oncology/critical care. Eisai manufactures Aricept, donepezil hydrochloride tablets, and Aciphex, rabeprazole sodium, in its existing facility.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.